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Myosins constitute a large and diverse superfamily of ATP-dependent motor 
proteins responsible for actin-based motility. Currently, based on phylogenetic analyses, 
myosins are classified into at least twenty four groups. The members of this superfamily 
are involved in several cell processes such as muscle contraction, cytokinesis, organelle 
transport, cell polarization and signal transduction. Thus, dysfunction and mutation of 
myosins can cause several diseases.  
Therefore, design of myosin inhibitors seems to be very attractive research field 
from the point of view of characterization of intracellular processes as well as 
development of novel targeted therapy against diseases implicating myosin dysfunction.  
Nowadays, one of the most well-known and widely used inhibitors of myosin is 
(S)-blebbistatin. This inhibitor of myosin II has many advantages, nevertheless it 
possesses also several limiting factors impeding the biological studies such as 
photosensitivity and low solubility in water.  
The aim of this Thesis was to synthetize novel blebbistatin derivatives in order to 
improve properties of the inhibitor and eliminate its disadvantageous qualities. Last but 
not least, novel derivatives were designed to exert higher affinity to particular myosin II 
isoforms, which could serve to more specific characterization of myosin II functions.  
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Myosiny tvoří velkou a rozmanitou skupinu ATP-dependentních motorových 
proteinů zodpovědných za motilitu na aktinových vláknech. Současné fylogenetické 
analýzy rozdělují myosiny do nejméně dvaceti čtyř tříd. Zástupci těchto skupin se podílejí 
na mnoha buněčných procesech, jako je svalová kontrakce, cytokineze, transport organel, 
polarizace buňky a transdukce signálu. Proto dysfunkce a mutace myosinu mohou být 
příčinou některých onemocnění.  
Vývoj inhibitorů myosinu se zdá být velice atraktivní oblastí výzkumu z pohledu 
jak charakterizace vnitřních buněčných procesů, tak i vývoje cílené léčby onemocnění 
spojených s myosinovou dysfunkcí.  
Jedním z nejznámějších a nejpoužívanějších inhibitorů myosinu v současné době 
je (S)-blebbistatin. Využití tohoto inhibitoru jako malého molekulového nástroje má 
mnoho výhod, přesto se však u něj vyskytují některé limitující faktory, které omezují jeho 
použití při biologických studiích, jako je například fotosensitivita a nízká rozpustnost ve 
vodě. 
Cílem této práce bylo připravit nové deriváty blebbistatinu za účelem zlepšení 
biologického profilu tohoto inhibitoru a odstranění jeho nežádoucích vlastností. 
V neposlední řadě nutno zmínit, že nové deriváty byly navrženy tak, aby vykazovaly 
vyšší afinitu k jednotlivým izoformám myosinu II, což by napomohlo k podrobnější 
charakterizaci funkcí myosinu. 
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ADP adenosine diphosphate 
ATP adenosine triphosphate 
ATPase adenosine triphosphatase 
BDM 2,3-butanedione monoxime 
BTS N-benzyl-p-toluene sulfonamide 
DCM dichloromethane 
DMA dimethylacetamide 
DMSO dimethyl sulfoxide 
ee enantiomeric excess 
EtOAc ethyl acetate 
GFP green fluorescent protein 
HPLC high-performance liquid chromatography 
IC50 half maximal inhibitory concentration 
LRMS low resolution mass spectrometry 
MeOH methanol 
MgSO4 magnesium sulphate 
MHC myosin heavy chain 
MLC myosin light chain 
MTBE methyl tert-butyl ether 
NMII non-muscle myosin II 
PBP pentabromopseudilin 
PClP pentachloropseudilin 
PE petroleum ether 
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Pi inorganic phosphate 
POCl3 phosphoryl chloride 
RNA ribonucleic acid 
RT room temperature 
SAR structure-activity relationship 





2 AIM OF THE WORK 
The aim of this work is to design and prepare novel blebbistatin derivatives as 
potential myosin inhibitors with enhanced or modified properties compare to original 
compound based on structural research of already reported blebbistatin analogues.  
Additionally, another goal is to optimize and find alternative methods for an 
amidine synthesis, which is a low-yielded reaction in (S)-blebbistatin synthesis in order 
to get better yields as well as suggest a different synthetic strategy that allows for easier 




3 THEORETICAL PART 
3.1 MYOSIN SUPERFAMILY 
3.1.1 INTRODUCTION OF MYOSINS 
Myosin superfamily is a large and diverse group of ATP-dependent actin-based 
motor proteins, which are involved in several cellular processes such as muscle 
contraction, cytokinesis, organelle transport, cell polarization, apoptosis, phagocytosis, 
exocytosis and signal transduction.[1- 4]  
Based on phylogenetic analyses of conserved structural domains this superfamily 
can be divided into at least twenty four classes (Figure 1). Twelve of these classes are 
expressed in mammalian cells (I-III, V-VII, IX, X, XV, XVI, XVII, and XIX).[2,3] 
Particular myosins occur in different organs or cell types based on their structural 
and functional characteristics. The first described myosin was isolated from the muscle 
cells, now denoted as muscle myosin II. Nevertheless, the majority of the members of the 
myosin superfamily are non-muscle myosins, so called unconventional myosins 
abounding mainly in cytoplasm. 
3.1.2 CONVENTIONAL MYOSINS 
The myosin II class, also known as conventional myosins, is the most thoroughly 
studied and described class of myosin superfamily. As mentioned above, the first myosin 
was identified in muscle extracts by Willy Kühne in 1864.[1]  
Besides muscle myosin II which is responsible for contraction of cardiac, skeletal 
and smooth muscles, there is the other member of this class, which is present in all non-
muscle eukaryotic cells – non-muscle myosin II (NMII). This myosin is involved in cell 
adhesion, division and migration. Paradoxically, NMII also occurs in muscle cells, where 
it fulfils distinct functions in the process of skeletal muscle development and 
differentiation, as well as sustention of tension in smooth muscles.[5]  
One of the structural hallmarks for this class is a dimeric unit able to form thick 
filaments.  
3.1.3 UNCONVENTIONAL MYOSINS  
Unconventional myosins is a group of relatively recently discovered motor 
proteins, which can be monomeric or dimeric, but compared to conventional myosins, it 
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is assumed that they are not able to form filaments.[6] For better understanding of the 
topic, a brief introduction of several the most important members of this group has been 
done below. 
Myosin I was the first described unconventional myosin. It can be found in 
Acanthamoeba, Dictyostelium, Saccharomyces, Emiricella (Aspergillus), chicken, mice, 
rats and humans. The members of this class are monomers divided into four subclasses. 
Their functioning influences processes such as cell crawling, chemotaxis, phagocytosis 
or cell division.[7]  
Myosin III was firstly isolated from Drosophila eye. Further, it can be found in 
horseshoe crabs, fish and humans. The function of this class is involved in 
phototransduction.[7] 
Myosin V has been identified in Drosophila, Caenorhabditis elegans, yeast, 
chicken, rats and humans.[6] This class of myosins has an important role in cargo 
transport, such as organelle, vesicle and RNA transport. Furthermore, it may be involved 
in chromosomal segregation, acrosome formation and nuclear morphogenesis during the 
process of spermatogenesis.[3]   
Myosin VI has been found in Drosophila, Caenorhabditis elegans, pigs, mice, 
chicken and humans. This class of myosins is presumably responsible for anchoring of 
stereocilia rootlets.[8]  
Myosin VII occurs in Drosophila, Caenorhabditis elegans, mice, pigs and 
humans. Two types of this myosin have been described so far, VIIA and VIIB. Very little 
is known about the function of myosin VII. More studied myosin VIIA is involved in 
stereocilia integrity and in membrane trafficking in the inner ear hair cells.[8]  
Myosin VIII, XI and XIII have been identified in higher plants. Several studies 






Figure 1. Myosin superfamily tree based on phylogenetic analyses. (Taken up from reference  [10]) 
 
3.1.4 MYOSIN STRUCTURE 
Generally, all myosins are composed of one or two heavy chains, forming the 
basic structure of the protein, and several light chains, having a modulatory and regulatory 
functions. The heavy chains are organized into three structurally and functionally 
different domains[4] (Figure 2): 
- N-terminal head (motor) domain containing actin-binding regions as well as Mg2+ 
ATPase site. This head domain is the most conserved region among the myosin 
superfamily and is responsible for force generation.  
- Central α-helical neck or lever-arm region, which binds to modulatory light chains 
or calmodulin. This region increases smaller movements within the catalytic 
domain during the chemo-mechanical ATPase cycle.  
- C-terminal tail domain mediating cargo-binding and intracellular targeting. This 




Figure 2. Myosin structures. (Taken up from reference [11]) 
 
3.1.5 MOLECULAR MECHANISM – ATPASE CYCLE  
Movement of myosin along the actin filament requires energy, which is obtained 
by hydrolysis of ATP by actin-activated ATPase in the motor domain. This process can 
be described in several steps (Figure 3).  
Myosin free of ATP binds tightly to actin in “rigor” state. Binding of ATP to 
myosin causes conformational change resulting in dissociation of the myosin motor from 
actin. In this phase myosin repositions itself into a “cocked” state and hydrolyzes ATP to 
ADP and inorganic phosphate (Pi). Thereafter, stable myosin-ADP-Pi intermediate 
forms. Such intermediate rebinds actin and releases inorganic phosphate, which triggers 
the myosin “power stroke” resulting in motor movement along actin. Subsequently, ADP 
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is released and myosin forms the actomyosin “rigor” state ready to start the ATPase cycle 
again.[2] It is noteworthy that myosin head walks toward the (+)-end of actin filament.  
 
Figure 3. ATPase cycle of myosin motors. (Taken up from reference [12]) 
 
3.1.6 REGULATION OF MYOSIN ACTIVITY 
There are many possibilities to regulate the activity of myosins leading to changes 
in processes such as cell adhesion, polarity of migrating cells, morphogenesis and many 
other functions that myosins are involved in.[5] 
Generally, the simplest way how to regulate the myosin activity is 
phosphorylation of myosin chains, both myosin heavy chains (MHC) and myosin light 
chains (MLC). This phosphorylation is provided by a network of kinases.  
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Dozens of diverse kinases able to phosphorylate the MLCs have been discovered, 
e.g. myosin light chain kinase, coiled coil-containing kinase, citron kinase, leucine zipper 
interacting kinase.[5] The main difference between these kinases is their mode of 
activation and their localization in cells. 
Myosin II assembles into filaments. Phosphorylation of its MHCs causes changes 
in electrostatic interactions between particular MHCs  leading to disruption of myosin 
filaments[13] or prevention of their formation[5].  Among the kinases able to 
phosphorylate the heavy chains belong calmodulin kinase II, casein kinase II and the 
members of the protein kinase C family.[13]  
It is also worthy to mention a metastasis-associated protein S100A4, also known 
as MTs1, which directly binds the MHC IIA isoform and thus prevents filaments 
formation. Such interaction may affect cell polarization and membrane protrusion, which 
can increase cell migration and tumor metastasis.[13] 
3.1.7 DISEASES ASSOCIATED WITH MYOSIN MUTATIONS AND 
DYSFUNCTIONS 
It has been found that myosins are linked to several human diseases and genetic 
syndromes. For example, myosin VIIA mutations lead to non-syndromic deafness or 
Usher syndrome resulting in hearing loss and blindness.[1] Myosin VA mutation is 
connected to Griscelli syndrome, which is characterized by hypopigmentation and 
immunodeficiency.[1] Dysfunction of cardiac myosin II and myosin VI is involved in 
hypertrophic cardiomyopathy[2], and mutation of non-muscle myosin II can cause 
deafness[1].  
Last but not least, non-muscle myosins have been also implicated in cancer. Based 
on their cellular functions they can be either tumor progressive or suppressive.[14]  
Therefore, the development of small molecule myosin activators or inhibitors 
represents a great potential in order to help us to understand the mechanisms of such 
diseases or even to improve their treatment.  
3.2 INHIBITORS OF MYOSIN 
Generally, there are two types of inhibitors of protein kinases – competitive and 
uncompetitive. In myosin case, competitive inhibitors have several disadvantages, such 
as lack of selectivity (can also inhibit non-myosin ATPases) and furthermore, myosins 
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blocked by competitive ATPase inhibitors remain bound to actin thus physically 
impeding non-inhibited myosins to bind this actin site.  
Based on abovementioned findings, uncompetitive myosin inhibitors represent 
greater potential as they bind to the protein at the allosteric site outside the ATP binding 
pocket thus having no secondary effect on other ATPases/ATP-binding proteins.  
Among uncompetitive myosin inhibitors belong, for example, 
pentachloropseudilin (PClP), pentabromopseudilin (PBP), myoVin-1, N-benzyl-p-
toluene sulfonamide (BTS) or 2,3-butanedione monoxime (BDM). PClP, inhibitor of 
myosin I, is highly halogenated natural antibiotic and it affects enzyme by reducing 
coupling between actin and nucleotide-biding sites. In addition, PClP also inhibits myosin 
V and NMII at higher concentrations (IC50 > 90 µM). Another member of pseudilin 
family having similar properties as PClP is PBP isolated from Pseudomonas bromoutilis. 
PBP exhibits higher affinity to myosin V and moreover, besides the same mechanism of 
inhibition as PClP, it also reduces ADP dissociation, ATP binding and hydrolysis. 
Inhibitor of myosin V - myoVin-1, the pyrazolopyrimidine-based compound, hinders 
ADP release from a protein. BTS is an aryl sulfonamide derivative exhibiting high affinity 
to fast-twitch skeletal muscle myosin at the same time impeding both release of Pi and 
ADP. BDM, originally synthetized as acetylcholinesterase reactivator, is able to inhibit 
muscle contraction by affecting skeletal myosin II in the step of Pi dissociation.[2] Last 
but not least, the most well-known and widely used uncompetitive inhibitor of myosin is 
blebbistatin. This derivative of 1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-
4-one blocks myosin II activity by hindering the release of Pi from the myosin-ADP-Pi 
complex.[15] The graphical overview of mechanisms of aforementioned inhibitors is 
depicted in Figure 4 and Figure 5. 
The main focus of present work is characterization of blebbistatin and its 




Figure 4. Inhibitors of myosin. 
 
Figure 5. Inhibition mechanism of myosin inhibitors. BDM: 2,3-butanedione monoxime; BTS: N-benzyl-




3.3.1 INTRODUCTION OF (S)-BLEBBISTATIN 
As mentioned above, (S)-blebbistatin (Figure 6) is an uncompetitive inhibitor of 
non-muscle myosin II discovered by a high-throughput screening.[16] Additionally, it has 
been revealed that blebbistatin itself is a degradation product of the “aged” DMSO 
solution of azatacrine analogue, which does not exert inhibition activity towards non-




Figure 6. (S)-Blebbistatin. 
 
The name of the compound was derived from its ability to inhibit formation of 
cell blebs. Bleb is a protrusion or flexure of the cytoplasmic membrane caused by 
disconnection of cytoskeleton from the membrane. This process, also designated as 
blebbing, appears, for example, during apoptosis. Moreover, (S)-blebbistatin rapidly 
disrupts cell migration and cytokinesis as well as cleavage of furrow ingression, but it 
does not affect an assembly of cleavage furrow.[16] 
(S)-Blebbistatin has become a significant small molecule tool for studying of the 
myosin properties and functions in cell processes. Comparing to classical genetics and 
RNAi technology studies it has a huge advantage in the ability to reversibly control the 
activity of a protein (by washing it in or out). Other general advantages of small molecules 
are, for instance, easy application to cross-species studies, possibility of administration 
of the combination of small molecules, excellent temporal resolution, study of the 
function of essential or recessive genes and many others.[18] In addition, these selective 
and high affinity compounds principally do not interfere with other cellular processes.  
3.3.2 MECHANISM OF MYOSIN INHIBITION BY BLEBBISTATIN 
(S)-Blebbistatin inhibits NMII, as well as skeletal myosin II, exerting at the same 
time no effect on smooth muscle myosin II or myosins of other classes.[15] 
(S)-Blebbistatin binds to a motor domain of myosin, in particular to a hydrophobic 
pocket at the apex of the 50kDa cleft and does not compete with substrate for nucleotide 
binding sites.[19] As mentioned above, in the process of ATPase-cycle the motor domain 
of enzyme occurs in several conformational forms. The mechanism of inhibition consists 
in binding of blebbistatin to myosin-ADP-Pi intermediate (detached from actin filament) 
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resulting in a specific perturbation in the nucleotide binding pocket and stabilization of 
this complex.[15] Finally, the release of inorganic phosphate (Pi) is inhibited and evoking 
associated myosin power stroke, thus the myosin is not able to bind to actin filament to 
form a “rigor” state again (Figure 5).  
3.3.3 STRUCTURAL BASIS OF MYOSIN INHIBITION BY BLEBBISTATIN 
Although the blebbistatin binding pocket in myosin motor domain is one of the 
most conserved segments among the myosin superfamily, the slightest sequence and 
structural changes in this region give blebbistatin the ability to distinguish among myosin 
isoforms.[19] Therefore, it is very important to know, how blebbistatin interacts with the 
myosin.  
Allingham and co-workers have studied the binding mode of blebbistatin to 
Dictyostelium discoideum myosin II and they have revealed that it is controlled by the 
hydrophobic interactions.[20] The benzyl ring of (S)-blebbistatin is enveloped by the side 
chains of Leu262, Phe466, Glu467 and Val630, while the tetrahydropyrrolo ring and the 
oxo group interact with Ser456 and Ile471. The methylquinolinone moiety is clustered by 
Tyr261, Thr474, Tyr634, Gln637 and Leu641 (Figure 7).[20]  
Furthermore, it has been investigated how the sequence and structural differences 
of diverse myosins correlate with the level of inhibition by blebbistatin. Indeed, 
comparison of the homologous residues of rabbit skeletal muscle myosin II, non-muscle 
myosin IIB to those in D. discoideum myosin II, disclosed that Ser456, Thr474, Tyr634 
and Gln637 residues exert many variabilities among the myosin isoforms, thus 
influencing blebbistatin inhibition.[20]  
Moreover, the enantioselectivity for (S)-stereoisomer is explained by a formation 
of hydrogen bonds between the chiral hydroxy group of blebbistatin and Leu262 or 
Gly240. (R)-stereoisomer is not able to form such interactions thus exerting lower affinity 




Figure 7. A) (S)-Blebbistatin bound to D. discoideum myosin II. B) The blebbistatin-myosin binding site. 
Selected amino acid residues interacting with blebbistatin are displayed in green sticks representation.[20] 
(Taken up from reference [20]) 
 
In order to better understand structure-activity relationship of blebbistatin Lucas-
Lopez’s group synthetized a series of blebbistatin analogues differing in the position of 
methyl group of the quinolinone part (Figure 8).[19] Other SAR study investigated an 
impact of oxo and hydroxy functional groups on inhibitory activity of blebbistatin.[21] 
Based on the results of these studies, several findings can be deduced. The positioning of 
the methyl group at C5, C6, C7 or its absence still allows the molecule to fit in the 50kDA 
cleft of myosin II and keep its inhibition activity. On the other hand, methyl incorporation 
into C8 position hinders the compound to remain in the hydrophobic pocket, so such 
derivative has no effect on activity. In addition, it has been confirmed that conservation 
of oxo functional group at C4 and keeping the stereochemistry of the C3a chiral center 
are one of the essential factors for retaining its biological activity. Last but not least, the 
aromatic quinolinone moiety and the phenyl ring are essential as well for maintaining the 




Figure 8. (S)-Blebbistatin and its positional methyl analogues and demethylated derivative. 
 
These structure modifications also revealed that several analogues resulted in 
much higher selectivity among non-muscle myosin II isoforms, i.e. NMIIA (human), 
NMIIB (human), NMIIC (mouse).[21] Therefore an interesting direction in blebbistatin 
derivatives development has been uncovered, which can lead to discovery of even more 
potent and selective compounds than blebbistatin.  
3.3.4 PROS AND CONS OF (S)-BLEBBISTATIN 
As mentioned above, (S)-blebbistatin has many advantageous factors, such as 
possibility of reversible myosin inhibition by washing it out. Further, it was also 
confirmed that blebbistatin is a specific inhibitor of myosin class II, and that it does not 
inhibit any other myosin classes such as I, V, X or XV.[18] The inhibitory effect towards 
myosin ATPase of the compound was assessed by determination of its IC50 value which 
ranges in 0.5–5 µM.[16] 
Despite undoubted advantages of (S)-blebbistatin, there are also several 
limitations in its usage. For a purpose of study of protein distribution and function within 
a cell, the fluorescence microscopy techniques are usually performed. These experiments 
are very often based on green fluorescent protein (GFP) fusion with the investigated 
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protein. Thanks to GFP, proteins can be easily visualized by irradiation with light of 
wavelength 420–490 nm and consecutive collection of emitted light from the investigated 
protein.[18] Nevertheless, (S)-blebbistatin is fluorescent itself, as it exerts significant 
emission at 440 nm, which is in the GFP emission wavelength range. Therefore, usage of 
(S)-blebbistatin for the observations of the myosin functioning in live cells is limited, and 
it is necessary to perform these experiments by using an alternative fluorescent proteins 
(e.g. red fluorescent protein), which have different emission wavelength range. 
Furthermore, (S)-blebbistatin becomes phototoxic after prolonged exposure to the blue 
light (390–470 nm) resulting in degradation and generation of reactive oxygen species, 
which have not been identified so far.[22] Except light sensitivity of the compound, the 
other disadvantageous factor for biological studies is also the fact that after prolonged 
incubation in live cells blebbistatin has cytotoxic side effects even in the absence of 
irradiation.[23] Additionally, another limiting factor of the inhibitor is its low solubility 
in aqueous solutions. 
Therefore, development of novel blebbistatin derivatives has great potential in 
order to eliminate these limitations and improve or modify its specific properties. Indeed, 
several blebbistatin derivatives, that have been synthetized by this time, confirm this 
effort to be worthy.  
3.3.5 BLEBBISTATIN DERIVATIVES 
To date, few interesting blebbistatin derivatives with enhanced or novel properties 
have been reported.  
One of the directions in blebbistatin derivatives development is to improve their 
photostability compared to the reference molecule. It has been shown that introduction of 
nitro group into blebbistatin structure reduces the fluorescence emission in GFP 
wavelength range. In particular, it was a derivative synthetized by Patterson et al. – (S)-7-
nitro-blebbistatin (Figure 9).[18] This led to further investigation and in 2014 Képiró’s 
group introduced a photostable derivative – p-nitroblebbistatin (Figure 9).[23]  
p-Nitroblebbistatin with a nitro group at C4′ position seems to be a good candidate 
for replacement of (S)-blebbistatin for the study of myosin II role in biological processes. 
It has been proven that C4′ nitro substitution of blebbistatin does not alter its biological 
activity, as the IC50 values of blebbistatin and p-nitroblebbistatin towards D. discoideum 
myosin II were almost the same (2.33 ± 0.13 µM and 2.96 ± 0.45 µM, respectively). 
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Comparing to (S)-blebbistatin, the C4′ nitro-substituted derivative is non-cytotoxic, non-
phototoxic and non-fluorescence myosin II inhibitor. Thus p-nitroblebbistatin does not 
decompose upon blue light irradiation, its fluorescence is decreased by a hundred times 
and it does not affect the toxicity rate of the cells even after the 36 hours treatment with 
the compound. Therefore it can be claimed that (S)-blebbistatin can be adequately 
substituted by this derivative not only in biology within in vitro assays but also in 
treatment of human diseases.[23]  
In response to positive results of p-nitroblebbistatin, chloro-derivative was also 
published. However, p-chloroblebbistatin (Figure 9), a derivative with chlorine at C4′ 
position, did not exert as good results as nitro-derivative. Nonetheless, thanks to this 
blebbistatin analogue it has been found out that improved photostability is not necessarily 
accompanied by reduced phototoxicity.[23] 
Another interesting derivative is p-azidoblebbistatin (Figure 9), a derivative 
substituted at C4′ position by azido group also synthetized by Képiró and co-workers.[24] 
Besides similar inhibition properties as (S)-blebbistatin in conditions of the absence of 
UV irradiation, p-azidoblebbistatin forms covalently crosslinked complex with enzyme 
after the irradiation at 310 nm, non-toxic wavelength for cells and/or tissues. Therefore, 
this azido-derivative might be also considered as a novel tool with improved properties 
in structural studies of actomyosin contractility as well as in investigation of biological 




Figure 9. (S)-Blebbistatin and its derivatives. 
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4 EXPERIMENTAL PART 
4.1 OPTIMIZATION OF BLEBBISTATIN SYNTHESIS 
Current total synthesis of (S)-blebbistatin (5) (Scheme 1) published by Lucas-
Lopez and co-workers has one big drawback – low yielding amidine synthesis (28%, 
compound 3).[17] Such reaction exploits phosphoryl chloride (POCl3) as an activator of 
N-phenyl-2-pyrrolidone (2). Therefore, one of the aims of this work was to investigate, 
suggest and develop an alternative synthesis of amidine intermediate in order to achieve 
higher yield of this step.  
 
Scheme 1. Total synthesis of (S)-blebbistatin.[17] 
To optimize this step (Scheme 2) we have decided to use methyl anthranilate (6) 
as a starting compound and to substitute phosphoryl chloride by trifluoromethanesulfonic 
anhydride (triflic anhydride, Tf2O) supposing to be better activator of 2 than POCl3.The 
reaction was pursued under different conditions, such as diverse reaction time or different 
reaction temperatures. Firstly, we have tried to activate amide with Tf2O and pyridine 
according to the procedure described by Charette and Grenon[25] but unfortunately with 
no results even after changing the reaction conditions. Therefore, we have decided to 
change the protocol avoiding pyridine to let amide activate with Tf2O only.[26] Such 
conditions bore the fruit in the form of desired intermediate (7). Unfortunately, according 
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to HPLC analysis the conversion was not complete, therefore there was no reason to use 
these conditions for amidine synthesis instead of current protocol with POCl3. On the 
other hand, this can be still a hint for further investigation and development of more 
efficient amidine synthesis.  
 
Scheme 2. Alternative amidine synthesis with triflic anhydride. 
4.2 DESING OF NOVEL BLEBBISTATIN DERIVATIVES 
According to structural and binding site studies as well as to properties of 
blebbistatin derivatives, it can be assumed that there is still a place for new blebbistatin 
derivatives with enhanced or modified properties including selectivity to particular 
myosin II isoforms.[18] 
The best possibility for modification of (S)-blebbistatin (5) structure seems to be 
phenyl ring, but also quinolinone part, in particular at C6 or C7 position. As modifications 
of phenyl ring were studied by other groups, our task was to focus on quinolinone moiety 
of 5. Last but not least aim of our work was to develop alternative synthetic strategy 




Figure 10. (S)-Blebbistatin binding site and its interaction with amino acid residues (displayed in green 
sticks representation) in 50kDa pocket of D. discoideum myosin II at different angles. (Taken up from 
Protein Data Bank, accession code 1YV3, reference [27]). 
Generally, blebbistatin and its derivatives synthesis can be described in three basic 
steps, as depicted in Scheme 1. The first step has been already mentioned by formation 
of amidine intermediate. The second step exploits intramolecular Claisen-type 
condensation to form a quinolinone intermediate. In the last step, the quinolinone 
intermediate is stereoselectively oxidized by Davis oxaziridine to afford the final product. 
For reactions described below, stereoisomers (-)-(8,8-
dichlorocamphorylsulfonyl)oxaziridine (19) and (+)-(8,8-
dichlorocamphorylsulfonyl)oxaziridine (20) were used as Davis reagents prepared by 




Figure 11. Davis oxaziridines. (-)-Davis oxaziridine (19), (+)-Davis oxaziridine (20). These compounds 
were prepared by K. Wagner during his bachelor thesis research.[28] 
For know-how adoption already published analogue (S)-6-nor-blebbistatin (9) has 
been synthetized as well (Scheme 3).[19] 
 
Scheme 3. Synthesis of (S)-6-nor-blebbistatin (9). 
At first step of design of novel myosin II inhibitors, it was necessary to rationally 
propose their structures, respectively select potentially interesting functional groups that 
can be substituted at C6 position.  The primary direction of such study was to prolong an 
alkyl chain at C6 position. Thus both enantiomers of 6-ethyl-blebbistatin (16, 17) were 
prepared. The synthetic strategy consisted in development of an appropriate synthetic 
route which could be further applied in preparation of other blebbistatin derivatives at the 
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same time still using basic procedures from the total synthesis of (S)-blebbistatin. Thus 
the synthetic route yielding bromo-substituted intermediate (13) seemed to meet such 
requirements ().  
 
Scheme 4. Synthesis of ethyl-blebbistatin enantiomers. 
Due to successful synthesis of intermediate 13 it was not also difficult to obtain 





Scheme 5. Synthesis of bromo-blebbistatin derivatives. 
Subsequently, we have focused on the synthesis of ethynyl analogues (22, 23) 
(Scheme 6). Unfortunately, due to time deficiency, we did not manage to synthesize them. 
 
 




4.3 SYNTHESIS OF NOVEL BLEBBISTATIN DERIVATIVES 
Unless otherwise noted, starting materials and reagents were obtained from 
commercial suppliers and were used without further purification.  
All reactions were performed in flame dried glassware under protective 
atmosphere (N2 or Ar) if not stated otherwise. 
Analytical thin layer chromatography (TLC) was performed on Merck silica gel 
60 F254 supported on aluminum sheets; compounds were visualized using irradiation with 
ultraviolet light at 254 nm and/or 366 nm and/or by using the following staining solution 
(dip, dry & heat development). Staining solution: KMnO4 (1 g), K2CO3 (6.6 g), 5% NaOH 
(1.7 mL) in H2O (90 mL). 
Chromatographic separation was performed by flash column chromatography on 
silica gel 60 (40 – 63 μm, Merck) (approx. 0.3 bar positive pressure). 
Nuclear magnetic resonance (NMR) spectra were recorded on the following 
instruments: Bruker Avance I 250 (250/63 MHz), Bruker Fourier 300 (300/75 MHz), 
Bruker Avance I 400 (400/101 MHz) and Bruker Avance III 400 (400/101 MHz, Z-
gradient broad band observe or inverse probe). Chemical shifts (δ) are expressed in parts 
per million (ppm) with respect to the solvent signal (CDCl3-d, MeOH-d4, DMSO-d6) and 
spin multiplicities are given as s (singlet), bs (broad singlet), d (doublet), dd (doublet of 
doublets), t (triplet), q (quartet, p (pentet) or m (multiplet).  
LC-coupled electrospray mass spectrometric analyses (LRMS, ESI-MS) were 
performed on a Finnigan LCQ spectrometer operating in positive or negative ion mode. 
Calculated masses were obtained using the software ChemDraw Ultra (CambridgeSoft 
Corporation) or Xcalibur. 
HPLC analyses (achiral stationary phase: EC 125/4 Nucleodur C18 gravity, 5 µm, 
Macherey-Nagel) were conducted on a combined Shimadzu system (components: LC-
10AT, DGU-14A, SIL-10AD, SCL-10A, LC-10AT, CTO-10AC, SPD-M20A, SPD-
10A) using acetonitrile/water mixtures as mobile phase with a flow rate of 1 mL/min and 
detection at wavelengths of 203, 220 and 254 nm. The following gradients (MeCN:H2O) 
were employed: Method A: 50:50 → 95:5 in 10 min, 95:5 for 20 min; Method B 10:90 → 
95:5 in 15 min, 95:5 for 15 min.  
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Chiral HPLC analyses were conducted on a combined Shimadzu system 
(components: LC-10AT, DGU-14A, SIL-10AD, SCL-10A, LC-10AT, CTO-10AC, SPD-
M20A, SPD-10A) using a Daicel Chiralpak IA (5 µm, 250/4.6) as chiral stationary phase, 
isocratic n-hexane/ethanol mixtures (ratio see compound data) as mobile phase with a 
flow rate of 1 mL/min and detection at wavelengths of 203, 220 and 254 nm. 
For melting point determination a Büchi B-545 melting point apparatus and open 




4.3.1 SYNTHESIS OF (S)-6-NOR-BLEBBISTATIN (SCHEME 3) 
Methyl 2-[(E)-(1-phenylpyrrolidin-2-ylidene)amino]benzoate (7) 
To the solution of N-phenyl-2-pyrrolidone (2, 0.16 g, 1.0 mmol) in DCM (1 mL) 
phosphoryl chloride (101 µL, 1.1 mmol) was added dropwise and stirred at RT for 3 h. 
Then solution of methyl anthranilate (6, 0.15 mg, 1.0 mmol) in DCM (4 mL) was added 
and reaction mixture was refluxed for 16 h. Reaction mixture was cooled to RT and 
concentrated in vacuo. The solid residue was dissolved in aqueous hydrochloric acid 
solution (0.3 M, 30 mL) and extracted with DCM (3 × 30 mL). The aqueous layer was 
then basified with aqueous sodium hydroxide solution (2 M) to pH 8 and subsequently 
extracted with EtOAc (2 × 30 mL). The DCM extracts were concentrated in vacuo and 
the resulting solid was carried out according to the abovementioned procedure three times 
more. All EtOAc extracts were combined, dried over MgSO4, and concentrated in vacuo 
to afford 7 as white solid (206 mg).  
Yield: 70 % 
M. w.: 294.35 
Exact mass: 294.14 calculated for C18H18N2O2 
LRMS (ES+) m/z (%): 295 (100) [M + H]+ 
Rf: 0.45 (n-heptane:EtOAc 1:1) 
M. p.: 124 – 125 °C (127 – 128 °C in reference [19]) 
1H NMR (400 MHz, CDCl3-d) δ 7.89 – 7.81 (m, 3H), 7.43 – 7.33 (m, 3H), 7.12 – 6.99 
(m, 2H), 6.86 – 6.80 (m, 1H), 3.91 (t, J = 7.3 Hz, 2H), 3.84 (s, 3H), 2.50 (t, J = 7.4 Hz, 
2H), 2.08 (p, J = 7.3 Hz, 2H).  
13C NMR (101 MHz, CDCl3-d) δ 167.67, 159.40, 153.05, 141.52, 132.45, 130.76, 128.51, 





Solution of amidine intermediate 7 (0.10 g, 0.33 mmol) in THF (25 mL) was cooled to -
78 °C and stirred for 15 min. Lithium bis(trimethylsilyl)amide (1.0 mL, 1.0 M in 
THF/hexane) was added dropwise to the reaction mixture, warmed to 0 °C and stirred for 
3 h. The reaction was quenched with saturated aqueous ammonium chloride solution (2 
mL). Additional aqueous ammonium chloride solution (50 mL) was added. The aqueous 
phase was extracted with DCM (3 × 30 mL). Combined organic extracts were dried over 
MgSO4 and concentrated to dryness. Purification by column chromatography on silica gel 
eluting with DCM:MeOH 20:1 (Rf = 0.34) afforded off-white solid (78 mg). 
Yield: 91 % 
M. w.: 262.31 
Exact mass: 262.11 calculated for C17H14N2O 
LRMS (ES+) m/z (%): 263 (100) [M + H]+ 
Rf: 0.34 (DCM:MeOH 20:1) 
M. p.: 181 – 182 °C (189 – 190 °C in reference [19]) 
1H NMR (250 MHz, DMSO-d6) δ 8.16 – 8.03 (m, 2H), 7.99 (d, J = 7.4 Hz, 1H), 7.61 (d, 
J = 8.0 Hz, 1H), 7.54 – 7.46 (m, 1H), 7.47 – 7.34 (m, 2H), 7.30 – 7.17 (m, 1H), 7.10 – 
6.95 (m, 1H), 4.10 (t, J = 8.0 Hz, 2H), 3.19 (t, J = 7.9 Hz, 2H).  
13C NMR (63 MHz, DMSO-d6) δ 143.43, 129.99, 129.91, 127.28, 123.42, 123.07, 122.72, 







To the solution of quinolone intermediate 7 (0.015 g, 0.06 mmol) in THF (3 mL) cooled 
to -78 °C solution of lithium bis(trimethylsilyl)amide (69 µL, 1.0 M in THF) was added 
dropwise. The reaction mixture was stirred at -78 °C for 30 min. Subsequently solution 
of (-)-Davis reagent 19 (0.041 g, 0.14 mmol) in THF (3 mL) was added. The reaction 
mixture was stirred and slowly warmed to -10 °C over 16 h. The reaction was quenched 
with saturated aqueous ammonium chloride solution (5 mL) at -10 °C. MTBE (5 mL) was 
added and the reaction mixture was warmed to RT. Further, saturated aqueous sodium 
thiosulfate solution (5 mL) was added and reaction mixture was extracted with MTBE (2 
× 15 mL). Collected organic layers were dried over MgSO4 and concentrated to dryness. 
The resulting solid was partitioned between DCM (100 mL) and aqueous hydrochloric 
acid solution (0.3 M, 100 mL). The aqueous layer was washed with DCM (3 × 100 mL), 
basified with aqueous sodium hydroxide solution (2.0 M) to pH 8 and extracted with 
EtOAc (2 × 100 mL). Ethyl acetate organic extracts were dried over MgSO4 and 
concentrated in vacuo to get desired final product 9 as bright yellow solid. Subsequently, 
compound 9 was recrystallized from acetonitrile (9 mg). 
Yield: 57 % 
M. w.: 278.31 
Exact mass: 278.11 calculated for C17H14N2O2 
LRMS (ES+) m/z (%): 279 (100) [M + H]+ 
Rf: 0.30 (DCM:MeOH 30:1) 
M. p.: 191 – 192 °C (melting point was not determined in reference [19]) 
ee 70 % as determined by chiral HPLC analysis (n-hexane-ethanol 96.25 : 3.75, major 
enantiomer: tR = 41.26 min, minor enantiomer: tR = 47.99 min). 
1H NMR (300 MHz, CDCl3-d:MeOH-d4 10:1) δ 7.89 – 7.77 (m, 3H), 7.52 – 7.33 (m, 3H), 
7.25 – 7.11 (m, 2H), 7.08 – 6.98 (m, 1H), 4.27 – 4.09 (m, 1H), 3.87 (t, J = 9.1 Hz, 1H), 
2.53 – 2.35 (m, 1H), 2.33 – 2.13 (m, 1H).  
13C NMR (75 MHz, CDCl3-d:MeOH-d4 10:1) δ 195.21, 165.46, 151.48, 139.94, 136.36, 
128.92, 127.19, 126.06, 124.81, 123.48, 120.92, 73.31, 29.64, 29.06.  
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4.3.2 SYNTHESIS OF 6-ETHYL ANALOGUE OF BLEBBISTATIN (SCHEME 4) 
Methyl 2-amino-5-bromobenzoate (11) 
To the solution of 5-bromoantranilic acid (10, 2.0 g, 9.26 mmol) in anhydrous MeOH (50 
mL) cooled to 0 °C thionyl chloride (1.7 mL, 23.15 mmol) was added dropwise. The 
reaction mixture was refluxed for 24 h. The solvent was evaporated. Saturated aqueous 
sodium bicarbonate solution (100 mL) was added to crude residue and extracted with 
MTBE (3 × 100 mL). Combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated to dryness. Purification by column chromatography on silica 
gel eluting with petroleum ether:EtOAc 2:1 (Rf = 0.85) gave the desired product 11 as 
yellowish solid (1.26 g). 
Yield: 59 % 
M. w.: 230.06 
Exact mass: 228.97 calculated for C8H8BrNO2 
LRMS (ES+) m/z (%): 231 (100) [M + H]+ 
Rf: 0.85 (PE:EtOAc 2:1) 
M. p.: 73 – 74 °C  
1H NMR (300 MHz, CDCl3-d:MeOH-d4 10:1) δ 7.89 – 7.77 (m, 3H), 7.52 – 7.33 (m, 3H), 
7.25 – 7.11 (m, 2H), 7.08 – 6.98 (m, 1H), 4.27 – 4.09 (m, 1H), 3.87 (t, J = 9.1 Hz, 1H), 
2.53 – 2.35 (m, 1H), 2.33 – 2.13 (m, 1H).  
13C NMR (75 MHz, CDCl3-d:MeOH-d4 10:1) δ 195.21, 165.46, 151.48, 139.94, 136.36, 




Methyl 5-bromo-2-[(E)-(1-phenylpyrrolidin-2-ylidene)amino]benzoate (12) 
To the solution of N-phenyl-2-pyrrolidone (2, 0.35 g, 2.17 mmol) in DCM (3 mL) 
phosphoryl chloride (219 µL, 2.4 mmol) was added dropwise and stirred at RT for 3 h. 
Then solution of methyl 5-bromoanthranilate (11, 219 µL, 2.17 mmol) in DCM (12 mL) 
was added and the reaction mixture was refluxed for 16 h. Reaction mixture was cooled 
to RT and concentrated in vacuo. The solid residue was dissolved in aqueous hydrochloric 
acid solution (0.3 M, 100 mL) and extracted with DCM (3 × 100 mL). The aqueous layer 
was then basified with aqueous sodium hydroxide solution (2 M) to pH 8 and extracted 
with EtOAc (2 × 100 mL). The DCM extracts were concentrated in vacuo and the 
resulting solid was carried out according to the abovementioned procedure three times 
more. All EtOAc extracts were combined, dried over MgSO4, and concentrated in vacuo 
to get the desired product 12 as off-white oil (180 mg). 
Yield: 22 % 
M. w.: 373.24 
Exact mass: 372.05 calculated for C18H17BrN2O2 
LRMS (ES+) m/z (%): 374 (100) [M + H]+ 
Rf: 0.24 (PE:EtOAc 4:1) 
1H NMR (300 MHz, CDCl3-d) δ 7.98 (d, J = 2.4 Hz, 1H), 7.83 – 7.74 (m, 2H), 7.46 (dd, 
J = 8.5, 2.4 Hz, 1H), 7.41 – 7.32 (m, 2H), 7.13 – 7.04 (m, 1H), 6.71 (d, J = 8.5 Hz, 1H), 
3.89 (t, J = 7.3 Hz, 2H), 3.84 (s, 3H), 2.47 (t, J = 7.4 Hz, 2H), 2.14 – 2.00 (m, 2H).  
13C NMR (75 MHz, CDCl3-d) δ 166.26, 159.78, 152.35, 141.14, 135.45, 133.48, 133.44, 





Solution of amidine intermediate 12 (0.28 g, 0.75 mmol) in THF (25 mL) was cooled to 
-78 °C and stirred for 15 min. Lithium bis(trimethylsilyl)amide (2.25 mL, 1.0 M in 
THF/hexane) was added dropwise to the reaction mixture, warmed to 0 °C and stirred for 
3 h. The reaction was quenched with saturated aqueous ammonium chloride solution (5 
mL). Additional aqueous ammonium chloride solution (100 mL) was added. The aqueous 
phase was extracted with DCM (3 × 100 mL). Combined organic extracts were dried over 
MgSO4 and concentrated to dryness. Purification by column chromatography on silica gel 
eluting with DCM:MeOH 20:1 (Rf = 0.26) afforded the desired product 13 as off-white 
solid (183 mg). 
Yield: 72 % 
M. w.: 341.20 
Exact mass: 340.02 calculated for C17H13BrN2O 
LRMS (ES+) m/z (%): 342 (100) [M + H]+ 
Rf: 0.26 (DCM:MeOH 20:1) 
M. p.: 154 –155 °C 
1H NMR (300 MHz, DMSO-d6) δ 10.82 (bs, 1H), 8.14 – 7.94 (m, 3H), 7.62 – 7.47 (m, 
2H), 7.43 – 7.31 (m, 2H), 7.08 – 6.95 (m, 1H), 4.07 (t, J = 7.9 Hz, 2H), 3.16 (t, J = 7.8 
Hz, 2H).  
13C NMR (75 MHz, DMSO-d6) δ 160.71, 153.42, 147.49, 142.26, 131.80, 129.03, 123.80, 





To the solution of corresponding quinolinone intermediate 13 (0.08 g, 0.23 mmol) in 
DMA (10 mL) were successively added: stock solution of Ni(dppe)Cl2 (5 mol%) and 
stock solution of neat diethylzinc (0.11 g, 0.92 mmol) in DMA (5 mL). The reaction 
mixture was stirred at 50 °C for 16 h. Subsequently, the reaction mixture was quenched 
with MeOH (5 mL) and thereafter saturated aqueous ammonium chloride solution (5 mL) 
was added. The mixture was extracted with MTBE (3 × 20 ml). Collected organic layers 
were washed with brine, dried over MgSO4 and concentrated to dryness. Purification by 
column chromatography on silica gel using DCM:MeOH (30:1 → 20:1 → 10:1) as 
gradient eluent afforded desired product 14 as off-white solid (55 mg). 
Yield: 70 % 
M. w.: 290.36 
Exact mass: 290.14 calculated for C19H18N2O 
LRMS (ES+) m/z (%): 292 (100) [M + H]+ 
Rf: 0.24 (DCM:MeOH 30:1) 
M. p.: 120 – 121 °C 
1H NMR (300 MHz, DMSO-d6) δ 8.02 (d, J = 7.3 Hz, 2H), 7.78 (d, J = 1.5 Hz, 1H), 7.52 
(d, J = 8.4 Hz, 1H), 7.43 – 7.28 (m, 3H), 7.06 – 6.93 (m, 1H), 4.06 (t, J = 8.1 Hz, 2H), 
3.15 (t, J = 8.1 Hz, 2H), 2.70 (q, J = 7.5 Hz, 2H), 1.23 (t, J = 7.6 Hz, 3H).  
13C NMR (75 MHz, DMSO-d6) δ 142.55, 137.55, 129.64, 129.00, 1241.39, 119.91, 






To the solution of quinolone intermediate 14 (0.023 g, 0.08 mmol) in THF (4 mL) cooled 
to -78 °C solution of lithium bis(trimethylsilyl)amide (100 µL, 1.0 M in THF) was added 
dropwise. The reaction mixture was stirred at -78 °C for 30 min. Solution of (-)-Davis 
reagent 19 (0.061 g, 0.2 mmol) in THF (5 mL) was added. The reaction mixture was 
stirred and slowly warmed to -10 °C during 16 h. The reaction was quenched with 
saturated aqueous ammonium chloride solution (5 mL) at -10 °C. MTBE (5 mL) was 
added and the reaction mixture was warmed to RT. Further saturated aqueous sodium 
thiosulfate solution (5 mL) was added and reaction mixture was extracted with MTBE (2 
× 15 mL). Collected organic layers were dried over MgSO4 and concentrated in vacuo. 
The resulting solid was partitioned between dichloromethane (100 mL) and aqueous 
hydrochloric acid solution (0.3 M, 100 mL). The aqueous phase was washed with 
dichloromethane (3 × 100 mL), basified with aqueous sodium hydroxide solution (2.0 M) 
to pH 8 and extracted with EtOAc (2 × 100 mL). The ethyl acetate organic extracts were 
dried over MgSO4 and concentrated to dryness to get the desired final product 15 as 
bright yellow solid. Subsequently, compound 15 was recrystallized from acetonitrile (12 
mg). 
Yield: 50 % 
M. w.: 306.36 
Exact mass: 306.14 calculated for C19H15N2O2 
LRMS (ES+) m/z (%): 307 (100) [M + H]+ 
Rf: 0.24 (DCM:MeOH 30:1) 
M. p.: 170 – 171 °C 
ee 88 % as determined by chiral HPLC analysis (n-hexane-ethanol 96.25 : 3.75, major 
enantiomer: tR = 31.45 min, minor enantiomer: tR = 39.28 min). 
1H NMR (300 MHz, CDCl3-d:MeOH-d4 10:1) δ 7.81 (d, J = 7.8 Hz, 2H), 7.64 (d, J = 2.0 
Hz, 1H), 7.44 – 7.33 (m, 2H), 7.32 – 7.28 (m, 1H), 7.20 – 7.08 (m, 2H), 4.20 – 4.06 (m, 
1H), 3.85 (t, J = 9.0 Hz, 1H), 2.58 (q, J = 7.6 Hz, 2H), 2.48 – 2.35 (m, 1H), 2.31 – 2.14 




13C NMR (75 MHz, CDCl3-d:MeOH-d4 10:1) δ 195.40, 165.09, 149.26, 140.02, 139.64, 





To the solution of quinolone intermediate 14 (0.023 g, 0.08 mmol) in THF (4 mL) cooled 
to -78 °C solution of lithium bis(trimethylsilyl)amide (100 µL, 1.0 M in THF) was added 
dropwise. The reaction mixture was stirred at -78 °C for 30 min. Solution of (+)-Davis 
reagent 20 (0.061 g, 0.2 mmol) in THF (0.04 mmol/1 mL) was added. The reaction 
mixture was stirred and slowly warmed to -10 °C over 16 h. The reaction was quenched 
with saturated aqueous ammonium chloride solution (5 mL) at -10 °C. MTBE (5 mL) was 
added and the reaction mixture was warmed to RT. Further saturated aqueous sodium 
thiosulfate solution (5 mL) was added and reaction mixture was extracted with MTBE (2 
× 15 mL). Combined organic extracts were dried over MgSO4 and concentrated in vacuo. 
The resulting solid was partitioned between dichloromethane (100 mL) and aqueous 
hydrochloric acid solution (0.3 M, 100 mL). The aqueous phase was washed with DCM 
(3 × 100 mL), basified with aqueous sodium hydroxide solution (2.0 M) to pH 8 and 
extracted with EtOAc (2 × 100 mL). Ethyl acetate organic layers were dried over MgSO4 
and concentrated in vacuo to obtain desired final product 16 as bright yellow solid. 
Subsequently, compound 16 was recrystallized from acetonitrile (12 mg). 
Yield: 50 % 
M. w.: 306.36 
Exact mass: 306.14 calculated for C19H15N2O2 
LRMS (ES+) m/z (%): 307 (100) [M + H]+ 
Rf: 0.24 (DCM:MeOH 30:1) 
M. p.: 170 – 171 °C 
ee 98 % as determined by chiral HPLC analysis (n-hexane-ethanol 96.25 : 3.75, major 
enantiomer: tR = 39.28 min, minor enantiomer: tR = 31.69 min). 
1H NMR (300 MHz, CDCl3-d:MeOH-d4 10:1) δ 7.82 (d, J = 7.9 Hz, 2H), 7.69 – 7.61 (m, 
1H), 7.45 – 7.33 (m, 2H), 7.33 – 7.28 (m, 1H), 7.20 – 7.08 (m, 2H), 4.23 – 4.05 (m, 1H), 
3.85 (t, J = 9.0 Hz, 1H), 2.59 (q, J = 7.6 Hz, 2H), 2.50 – 2.33 (m, 1H), 2.32 – 2.12 (m, 




13C NMR (75 MHz, CDCl3-d:MeOH-d4 10:1) δ 195.42, 165.08, 149.29, 140.04, 139.65, 
136.23, 128.88, 125.96, 124.62, 120.78, 120.58, 73.26, 29.06, 28.03, 15.36.  
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4.3.3 SYNTHESIS OF 6-BROMO ANALOGUE OF BLEBBISTATIN (SCHEME 5) 
(3aS)-6-Bromo-3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one (17) 
To the solution of quinolone intermediate 13 (0.029 g, 0.085 mmol) in THF (4 mL) cooled 
to -78 °C solution of lithium bis(trimethylsilyl)amide (100 µL, 1.0 M in THF) was added 
dropwise. The reaction mixture was stirred at -78 °C for 30 min. Solution of (-)-Davis 
reagent 19 (0.061 g, 0.2 mmol) in THF (0.04 mmol/1 mL) was added. The reaction 
mixture was stirred and slowly warmed to -10 °C over 16 h. The reaction was quenched 
with saturated aqueous ammonium chloride solution (5 mL) at -10 °C. MTBE (5 mL) was 
added and the reaction mixture was warmed to RT. Further saturated aqueous sodium 
thiosulfate solution (5 mL) was added and reaction mixture was extracted with MTBE (2 
× 15 mL). Combined organic extracts were dried over MgSO4 and concentrated in vacuo. 
The resulting solid was partitioned between dichloromethane (100 mL) and aqueous 
hydrochloric acid solution (0.3 M, 100 mL). The aqueous phase was washed with DCM 
(3 × 100 mL), basified with aqueous sodium hydroxide solution (2.0 M) to pH 8 and 
extracted with EtOAc (2 × 100 mL). Ethyl acetate organic layers were dried over MgSO4 
and concentrated in vacuo to obtain the desired final product 17 as bright yellow solid. 
Subsequently, compound 17 was recrystallized from acetonitrile (19 mg). 
Yield: 63 % 
M. w.: 357.20 
Exact mass: 356.02 calculated for C17H13BrN2O2 
LRMS (ES+) m/z (%): 358 (100) [M + H]+ 
Rf: 0.47 (DCM:MeOH 30:1) 
M. p.: 199 – 200 °C 
ee 98 % as determined by chiral HPLC analysis (n-hexane-ethanol 85 : 15, major 
enantiomer: tR = 14.20 min, minor enantiomer: tR = 15.20 min). 
1H NMR (300 MHz, CDCl3-d:MeOH-d4 10:1) δ 7.89 (d, J = 2.3 Hz, 1H), 7.80 (d, J = 7.8 
Hz, 2H), 7.51 (dd, J = 8.5, 2.4 Hz, 1H), 7.45 – 7.34 (m, 2H), 7.22 – 7.12 (m, 1H), 7.08 
(d, J = 8.6 Hz, 1H), 4.23 – 4.07 (m, 1H), 3.87 (t, J = 9.1 Hz, 1H), 2.48 – 2.35 (m, 1H), 
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2.31 – 2.17 (m, 1H).  
13C NMR (75 MHz, CDCl3-d:MeOH-d4 10:1) δ 193.97, 165.53, 150.50, 139.66, 138.63, 





To the solution of quinolone intermediate 13 (0.029 g, 0.085 mmol) in THF (4 mL) cooled 
to -78 °C solution of lithium bis(trimethylsilyl)amide (100 µL, 1.0 M in THF) was added 
dropwise. The reaction mixture was stirred at -78 °C for 30 min. The solution of (+)-
Davis reagent 20 (0.061 g, 0.2 mmol) in THF (0.04 mmol/1 mL) was added. The reaction 
mixture was stirred and slowly warmed to -10 °C over 16 h. The reaction was quenched 
with saturated aqueous ammonium chloride solution (5 mL) at -10 °C. MTBE (5 mL) was 
added and the reaction mixture was warmed to RT. Further saturated aqueous sodium 
thiosulfate solution (5 mL) was added and reaction mixture was extracted with MTBE (2 
× 15 mL). Combined organic layers were dried over MgSO4 and concentrated to dryness. 
The resulting solid was partitioned between dichloromethane (100 mL) and aqueous 
hydrochloric acid solution (0.3 M, 100 mL). The aqueous phase was washed with DCM 
(3 × 100 mL), basified with aqueous sodium hydroxide solution (2.0 M) to pH 8 and 
extracted with EtOAc (2 × 100 mL). Ethyl acetate organic layers were dried over MgSO4 
and concentrated in vacuo to obtain the desired final product 18 as bright yellow solid. 
Then compound 18 was recrystallized from acetonitrile (19 mg). 
Yield: 63 % 
M. w.: 357.20 
Exact mass: 356.02 calculated for C17H13BrN2O2 
LRMS (ES+) m/z (%): 358 (100) [M + H]+ 
Rf: 0.47 (DCM:MeOH 30:1) 
M. p.: 199 – 200 °C 
ee 98 % as determined by chiral HPLC analysis (n-hexane-ethanol 85 : 15, major 
enantiomer: tR = 15.18 min, minor enantiomer: tR = 14.15 min). 
1H NMR (300 MHz, CDCl3-d:MeOH-d4 10:1) δ 7.89 (d, J = 2.2 Hz, 1H), 7.80 (d, J = 7.9 
Hz, 2H), 7.51 (dd, J = 8.5, 2.3 Hz, 1H), 7.45 – 7.33 (m, 2H), 7.22 – 7.13 (m, 1H), 7.08 
(d, J = 8.5 Hz, 1H), 4.24 – 4.09 (m, 1H), 3.87 (t, J = 9.1 Hz, 1H), 2.51 – 2.33 (m, 1H), 




13C NMR (75 MHz, CDCl3-d:MeOH-d4 10:1) δ 193.98, 165.52, 150.51, 139.67, 138.63, 
129.55, 128.95, 127.77, 125.09, 122.24, 121.05, 115.98, 48.59, 28.96.  
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4.4 RESULTS AND DISCUSSION 
Present study was focused on synthesis of novel blebbistatin derivatives and 
searching for different or modified synthetic procedures providing easier synthesis of 5 
and its analogues.  
An interesting intermediate 13 has been synthetized from its precursor 12. 
Intermediate 13 constitutes a facile access to several other blebbistatin derivatives via 
bromine substitution. The assumption about the reactivity of bromine at C6 position was 
confirmed by successful conversion of compound 13 to compound 14 using Negishi 
coupling procedure. All these compounds are novel and have not been reported in 
literature so far. 
Synthesis of novel derivatives included at least one additional step – conversion 
of bromo-quinolinone intermediate 13 to another substituted quinolinone compound (, 
Scheme 6). Several cross coupling methods have been applied for preparation of ethyl 
derivative – primarily unsuccessful Suzuki-Miyaura[31] coupling, finally fruitful Negishi 
type coupling using Ni catalyst[29,30]. Sonogashira type coupling has been applied in an 
attempt to synthesize ethynyl compound 21, unfortunately with negative results. 
However, further optimization of this cross coupling type reaction might bring the desired 
outcome.[32,33]   
 As a result, five final products 9, 15, 16, 17, 18 were prepared as potential 
uncompetitive myosin inhibitors. Compound 9 have previously been reported by Lucas-
Lopez ae co-workers [17], the remaining products are new compounds. However, only 
the results of subsequent biological assays will help to characterize the properties of these 
compounds as well as relationship between the blebbistatin, its derivatives and myosin 
more specifically.  
Additionally, an alternative synthetic route to amidine synthesis (Scheme 2) was 
investigated with unsatisfactory results. However, this study left a hint, which can be 





The aim of this work was to prepare novel blebbistatin derivatives as potential 
small molecule myosin inhibitors. As myosin proteins are involved in several cell 
processes their dysfunctions and mutations can lead to a progression of diseases or genetic 
syndromes. Therefore, development of novel myosin inhibitors has a great potential in 
order to understand myosin cellular functions as well as to improve current treatment of 
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